<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440138</url>
  </required_header>
  <id_info>
    <org_study_id>BASECnr_2017-01652</org_study_id>
    <nct_id>NCT03440138</nct_id>
  </id_info>
  <brief_title>Defining Benchmarks in Bariatric Surgery</brief_title>
  <acronym>BBenchmarks</acronym>
  <official_title>Defining Benchmarks in Bariatric Surgery - A Global Analysis of Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco Bueter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. med. Daniel Gero</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. med. Dimitri A. Raptis, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. med. Henner Schmidt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To define benchmark outcomes in minimally-invasive primary bariatric surgery.

      Design: Multicenter retrospective cohort study.

      Assessed outcomes: Morbidity as defined by the Clavien-Dindo classification for surgical
      complications, the Comprehensive Complication Index® (CCI®) at discharge, at 3 months and at
      latest follow-up. Evolution of body mass index (BMI) will be also analyzed.

      Hospital eligibility: High volume centers (&gt; 200 bariatric operations per year) from at least
      three continents, maintaining a prospective database, as well as having published previously
      critically on their outcome.

      Study population: Adult patients who underwent primary minimally invasive (laparoscopic /
      robotic) Roux-en-Y gastric bypass or sleeve gastrectomy from 1st of June 2012 to 31st of May
      2017.

      Patient Exclusion criteria: detailed later.

      Data collection Deadline: 1st September 2017 - 30 April 2018
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background With the growing complexity and cost of modern surgical practice, quality
      assessment becomes mandatory. The notion of quality and quality assessment is widely
      recognized and used in the world of business and manufacturing. A possible tool of quality
      assessment is benchmarking. Benchmarking is a process of measuring performance by comparison
      to the outcomes achieved by the best &quot;service provider&quot; in a specific domain. Usually, a
      benchmark describes the ''best possible'' outcome of a benchmarking subject to whom
      comparison can be performed. In the surgical community, however, such benchmarks - best
      possible outcomes - for specific procedures, not just the pooled overall performance, are
      lacking.

      In 2016, a first landmark study defining benchmark outcomes for liver resection was published
      in Annals of Surgery by a group of international authors invited and guided by our
      department. More recently, further surgical outcomes (liver transplantation, minimally
      invasive esophagectomy) have been benchmarked and have been accepted for publication.

      Since laparoscopic bariatric surgery has become a standardized and widely performed procedure
      worldwide, quality assessment is of major importance. To identify the best possible outcomes
      (i.e. the benchmarks), data from high-volume centers (based on official IFSO criteria) in low
      risk patients will be analyzed. These benchmarks will serve as &quot;optimal outcomes&quot; for
      comparison with single center outcomes, high-risk patients and future developments.

      Aim The primary aim is to define benchmark outcomes based on assessment of post procedural
      complications according to the Clavien-Dindo classification for surgical complications and
      the comprehensive complication index CCI™ at discharge and at 90-days. The CCI® expresses
      morbidity on a continuous numeric scale from 0 (no complications) to 100 (death) by weighing
      all postoperative complications according to the Clavien-Dindo classification for their
      respective severity. Secondary outcome measure are patient survival and excess BMI loss
      (EBMIL).

      Data Security This multicenter international study is designed to harvest prospectively
      collected retrospective data via an encrypted (i.e. Secure Sockets Layer (SSL) protocol)
      online platform (https://bbenchmarks.org/) that meets Food and Drug Administration (FDA)
      standards and is accessible only by secured login membership.

      Confidential center specific data: Centers' outcomes will be individually analyzed in a first
      step to screen for center-specific differences. Benchmarks will be computed from each
      center's results in a second step. No center-specific data will be published. Instead, all
      complications or adverse outcomes will be anonymously reported, as fractions of the total
      study population. Each center, of course, will be free to publish their own data, as they
      wish.

      Further use of cohort data: Future studies based on the collected data may emerge from this
      multicenter study, such as comparing outcomes in patients with or without specific
      comorbidities with benchmark outcomes. For further data usage, additional ethics approval may
      be required.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Benchmark outcomes (best achievable outcomes after bariatric surgery)</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Comprehensive Complication Index (http://www.assessurgery.com/calculator_single/)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Benchmark outcomes (best achievable outcomes after bariatric surgery)</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Comprehensive Complication Index (http://www.assessurgery.com/calculator_single/)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Benchmark outcomes (best achievable outcomes after bariatric surgery)</measure>
    <time_frame>180 days postoperatively</time_frame>
    <description>Comprehensive Complication Index (http://www.assessurgery.com/calculator_single/)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major complications after bariatric surgery</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Clavien-Dindo grade &gt; IIIa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major complications after bariatric surgery</measure>
    <time_frame>90 days postoperatively</time_frame>
    <description>Clavien-Dindo grade &gt; IIIa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major complications after bariatric surgery</measure>
    <time_frame>180 days postoperatively</time_frame>
    <description>Clavien-Dindo grade &gt; IIIa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Benchmark outcomes (best achievable outcomes after bariatric surgery)</measure>
    <time_frame>5 years postoperatively</time_frame>
    <description>Comprehensive Complication Index (http://www.assessurgery.com/calculator_single/)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Case-mix within centers</measure>
    <time_frame>5 years</time_frame>
    <description>proportion of benchmark cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess weight loss after bariatric surgery</measure>
    <time_frame>1-year postoperatively</time_frame>
    <description>Body-mass index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess weight loss after bariatric surgery</measure>
    <time_frame>3-years postoperatively</time_frame>
    <description>Body-mass index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess weight loss after bariatric surgery</measure>
    <time_frame>5-years postoperatively</time_frame>
    <description>Body-mass index (kg/m2)</description>
  </secondary_outcome>
  <number_of_groups>19</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Benchmark</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Roux-en-y Gastric Bypass</condition>
  <condition>Sleeve Gastrectomy</condition>
  <condition>Complications</condition>
  <arm_group>
    <arm_group_label>University Hospital Zurich</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>St Pierre University Hospital, Brussels, Belgium</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sana Klinikum, Offenbach, Germany</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Complutense University of Madrid, Spain</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Musgrove Park Hospital, Taunton, UK</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>University of Gothenburg, Sweden</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>AZ Sint-Jan Hospital in Bruges, Belgium</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bristol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cleveland Clinic, Weston, Florida, USA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Oswaldo Cruz German Hospital, Sao Paolo, Brazil</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Clínica Las Condes, Santiago, Chile</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Brown University, Providence Rhode Island</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresno Bariatric, CA, USA</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rijnstate Hospital, Arnhem, The Netherlands</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CHU Nice, France</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Claraspital Basel, Switzerland</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastro-Obeso-Center Advanced Med Inst, Brazil</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital Dipreca Santiago Región Metropolitana , Chile</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical University Wien, Austria</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bariatric surgery (RYGB or SG)</intervention_name>
    <description>laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity</description>
    <arm_group_label>University Hospital Zurich</arm_group_label>
    <arm_group_label>St Pierre University Hospital, Brussels, Belgium</arm_group_label>
    <arm_group_label>Sana Klinikum, Offenbach, Germany</arm_group_label>
    <arm_group_label>Complutense University of Madrid, Spain</arm_group_label>
    <arm_group_label>Musgrove Park Hospital, Taunton, UK</arm_group_label>
    <arm_group_label>University of Gothenburg, Sweden</arm_group_label>
    <arm_group_label>AZ Sint-Jan Hospital in Bruges, Belgium</arm_group_label>
    <arm_group_label>Bristol</arm_group_label>
    <arm_group_label>Cleveland Clinic, Weston, Florida, USA</arm_group_label>
    <arm_group_label>Oswaldo Cruz German Hospital, Sao Paolo, Brazil</arm_group_label>
    <arm_group_label>Clínica Las Condes, Santiago, Chile</arm_group_label>
    <arm_group_label>Brown University, Providence Rhode Island</arm_group_label>
    <arm_group_label>Fresno Bariatric, CA, USA</arm_group_label>
    <arm_group_label>Rijnstate Hospital, Arnhem, The Netherlands</arm_group_label>
    <arm_group_label>CHU Nice, France</arm_group_label>
    <arm_group_label>Claraspital Basel, Switzerland</arm_group_label>
    <arm_group_label>Gastro-Obeso-Center Advanced Med Inst, Brazil</arm_group_label>
    <arm_group_label>Hospital Dipreca Santiago Región Metropolitana , Chile</arm_group_label>
    <arm_group_label>Medical University Wien, Austria</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with severe obesity with a lower risk profile who undergo bariatric surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of 18-65 years

          -  Low risk profile (please read &quot;exclusion criteria&quot;),

          -  Maximum preoperative BMI of 50 kg/m2

          -  Primary laparoscopic/robotic proximal Roux-en-Y gastric bypass or sleeve gastrectomy

          -  Documented follow-up of at least 90 days

        Exclusion Criteria:

          -  Open surgery

          -  Previous intra-abdominal surgery (including previous bariatric surgery)

          -  Pre-operative BMI over 50 kg/m2

          -  Age over 65 years

          -  Cardiovascular disease (e.g. cardiac arrhythmia, stroke, coronary artery disease)
             (Hypertension is allowed)

          -  History of thromboembolic events and/or therapeutic anticoagulation

          -  Diabetes mellitus (Type I and Type II, as defined by the American Diabetes
             Association)

          -  Obstructive sleep apnea (recurrent episodes of upper airway collapse during sleep)

          -  Chronic obstructive pulmonary disease (FEV1/FVC&lt;0.7)

          -  Chronic kidney disease (eGFR &lt; 30ml/min/1.72 m2)

          -  Inflammatory bowel disease (ulcerative colitis, Crohn's)

          -  Immunosuppression therapy (e.g. steroids, calcineurin inhibitors, etc)

          -  Patients who underwent associated procedures (for example: cholecystectomy,
             hiatoplasty, liver biopsy)

          -  ASA score &gt; 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marco Bueter, MD PhD</last_name>
    <phone>+41 44 255 8895</phone>
    <email>marco.bueter@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Bueter, MD, PhD</last_name>
      <phone>+41 44 255 8895</phone>
      <email>marco.bueter@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://bbenchmarks.org</url>
  </link>
  <reference>
    <citation>Rössler F, Sapisochin G, Song G, Lin YH, Simpson MA, Hasegawa K, Laurenzi A, Sánchez Cabús S, Nunez MI, Gatti A, Beltrame MC, Slankamenac K, Greig PD, Lee SG, Chen CL, Grant DR, Pomfret EA, Kokudo N, Cherqui D, Olthoff KM, Shaked A, García-Valdecasas JC, Lerut J, Troisi RI, De Santibanes M, Petrowsky H, Puhan MA, Clavien PA. Defining Benchmarks for Major Liver Surgery: A multicenter Analysis of 5202 Living Liver Donors. Ann Surg. 2016 Sep;264(3):492-500. doi: 10.1097/SLA.0000000000001849.</citation>
    <PMID>27433909</PMID>
  </reference>
  <reference>
    <citation>Muller X, Marcon F, Sapisochin G, Marquez M, Dondero F, Rayar M, Doyle MMB, Callans L, Li J, Nowak G, Allard MA, Jochmans I, Jacskon K, Beltrame MC, van Reeven M, Iesari S, Cucchetti A, Sharma H, Staiger RD, Raptis DA, Petrowsky H, de Oliveira M, Hernandez-Alejandro R, Pinna AD, Lerut J, Polak WG, de Santibañes E, de Santibañes M, Cameron AM, Pirenne J, Cherqui D, Adam RA, Ericzon BG, Nashan B, Olthoff K, Shaked A, Chapman WC, Boudjema K, Soubrane O, Paugam-Burtz C, Greig PD, Grant DR, Carvalheiro A, Muiesan P, Dutkowski P, Puhan M, Clavien PA. Defining Benchmarks in Liver Transplantation: A Multicenter Outcome Analysis Determining Best Achievable Results. Ann Surg. 2018 Mar;267(3):419-425. doi: 10.1097/SLA.0000000000002477.</citation>
    <PMID>28885508</PMID>
  </reference>
  <reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </reference>
  <reference>
    <citation>Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013 Jul;258(1):1-7. doi: 10.1097/SLA.0b013e318296c732.</citation>
    <PMID>23728278</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Marco Bueter</investigator_full_name>
    <investigator_title>Prof. Dr. med., PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>the study is based on de-anonymised data, so it is impossible to backtrack it to a patient. only overall data will be shared, not individual data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

